160 related articles for article (PubMed ID: 27981434)
21. Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension.
Higaki A; Mahmoud AUM; Paradis P; Schiffrin EL
Cardiovasc Res; 2021 Apr; 117(5):1274-1283. PubMed ID: 32870976
[TBL] [Abstract][Full Text] [Related]
22. Understanding Hypertension in Patients on Hemodialysis.
Kauric-Klein Z
Nephrol Nurs J; 2015; 42(1):69-75; quiz 76. PubMed ID: 26290920
[TBL] [Abstract][Full Text] [Related]
23. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
Jekell A; Malmqvist K; Wallén NH; Mörtsell D; Kahan T
J Cardiovasc Pharmacol; 2013 Dec; 62(6):559-66. PubMed ID: 24084214
[TBL] [Abstract][Full Text] [Related]
24. Hypercholesterolemia and Hypertension: Two Sides of the Same Coin.
Ivanovic B; Tadic M
Am J Cardiovasc Drugs; 2015 Dec; 15(6):403-14. PubMed ID: 26062915
[TBL] [Abstract][Full Text] [Related]
25. The role of the brain renin-angiotensin system in hypertension: implications for new treatment.
Marc Y; Llorens-Cortes C
Prog Neurobiol; 2011 Oct; 95(2):89-103. PubMed ID: 21763394
[TBL] [Abstract][Full Text] [Related]
26. Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.
Habib GB; Basra SS
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):516-25. PubMed ID: 24790054
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective.
Murray EC; Nosalski R; MacRitchie N; Tomaszewski M; Maffia P; Harrison DG; Guzik TJ
Cardiovasc Res; 2021 Nov; 117(13):2589-2609. PubMed ID: 34698811
[TBL] [Abstract][Full Text] [Related]
28. The immunological basis of hypertension.
Rodríguez-Iturbe B; Pons H; Quiroz Y; Johnson RJ
Am J Hypertens; 2014 Nov; 27(11):1327-37. PubMed ID: 25150828
[TBL] [Abstract][Full Text] [Related]
29. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
30. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
[TBL] [Abstract][Full Text] [Related]
31. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.
Savoia C; Schiffrin EL
Clin Sci (Lond); 2007 Jun; 112(7):375-84. PubMed ID: 17324119
[TBL] [Abstract][Full Text] [Related]
32. Endothelial dysfunction in essential hypertension.
Panza JA
Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-26-33. PubMed ID: 9422849
[TBL] [Abstract][Full Text] [Related]
33. Is there a future for direct renin inhibitors?
Chaudhary K; Nistala R; Whaley-Connell A
Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
[TBL] [Abstract][Full Text] [Related]
34. [Blockers of renin-angiotensin-aldosterone system in the treatment of arterial hypertension: classics versus the modern].
Kanorskiĭ SG
Kardiologiia; 2013; 53(10):89-95. PubMed ID: 24645559
[TBL] [Abstract][Full Text] [Related]
35. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
37. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.
Gullapalli N; Bloch MJ; Basile J
Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs which target the renin-angiotensin-aldosterone system.
Steckelings UM; Paulis L; Unger T; Bader M
Expert Opin Emerg Drugs; 2011 Dec; 16(4):619-30. PubMed ID: 21905943
[TBL] [Abstract][Full Text] [Related]
39. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
Abassi Z; Winaver J; Feuerstein GZ
Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
[TBL] [Abstract][Full Text] [Related]
40. Unmasking the potential of the angiotensin AT2 receptor as a therapeutic target in hypertension in men and women: what we know and what we still need to find out.
Hilliard LM; Mirabito KM; Denton KM
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):542-50. PubMed ID: 23406015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
